Brain-Derived Neurotrophic Factor (BDNF) as a Potential Biomarker in Brain Glioma: A Systematic Review and Meta-Analysis

Fatemeh Hasani; Mahdi Masrour; Sina Khamaki; Kimia Jazi; Erfan Ghoodjani; Antonio L. Teixeira

doi:10.1002/brb3.70266

Brain-Derived Neurotrophic Factor (BDNF) as a Potential Biomarker in Brain Glioma: A Systematic Review and Meta-Analysis

Fatemeh Hasani, Mahdi Masrour, Sina Khamaki, Kimia Jazi, Erfan Ghoodjani, Antonio L. Teixeira

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Background: This systematic review and meta-analysis evaluates peripheral and CNS BDNF levels in glioma patients. Methods: Following PRISMA guidelines, we systematically searched databases for studies measuring BDNF in glioma patients and controls. After screening and data extraction, we conducted quality assessment, meta-analysis, and meta-regression. Results: Eight studies were included. Meta-analysis showed significantly reduced plasma BDNF levels in glioma patients versus controls (SMD: −1.0026; 95% CI: [−1.5284, −0.4769], p = 0.0002). High-grade gliomas had lower plasma BDNF (p = 0.0288). Tissue BDNF levels were higher in glioma patients (SMD: 1.9513; 95% CI: [0.7365, 3.1661], p = 0.0016) and correlated with tumor grade (p = 0.0122). Plasma BDNF levels negatively correlated with patient age (p = 0.0244) and positively with female percentage (p = 0.0007). Conclusion: BDNF is a promising biomarker in glioma, showing significant changes in plasma and tissue levels correlating with tumor grade, patient age, and gender.

Original language	English (US)
Article number	e70266
Journal	Brain and Behavior
Volume	15
Issue number	1
DOIs	https://doi.org/10.1002/brb3.70266
State	Published - Jan 2025

Keywords

BDNF
biomarker
brain neoplasms
brain-derived neurotrophic factor
glioblastoma
glioma

ASJC Scopus subject areas

Behavioral Neuroscience

Access to Document

10.1002/brb3.70266

Cite this

@article{dda3ebb745a24e8ea04d1df448f9533d,

title = "Brain-Derived Neurotrophic Factor (BDNF) as a Potential Biomarker in Brain Glioma: A Systematic Review and Meta-Analysis",

abstract = "Background: This systematic review and meta-analysis evaluates peripheral and CNS BDNF levels in glioma patients. Methods: Following PRISMA guidelines, we systematically searched databases for studies measuring BDNF in glioma patients and controls. After screening and data extraction, we conducted quality assessment, meta-analysis, and meta-regression. Results: Eight studies were included. Meta-analysis showed significantly reduced plasma BDNF levels in glioma patients versus controls (SMD: −1.0026; 95% CI: [−1.5284, −0.4769], p = 0.0002). High-grade gliomas had lower plasma BDNF (p = 0.0288). Tissue BDNF levels were higher in glioma patients (SMD: 1.9513; 95% CI: [0.7365, 3.1661], p = 0.0016) and correlated with tumor grade (p = 0.0122). Plasma BDNF levels negatively correlated with patient age (p = 0.0244) and positively with female percentage (p = 0.0007). Conclusion: BDNF is a promising biomarker in glioma, showing significant changes in plasma and tissue levels correlating with tumor grade, patient age, and gender.",

keywords = "BDNF, biomarker, brain neoplasms, brain-derived neurotrophic factor, glioblastoma, glioma",

author = "Fatemeh Hasani and Mahdi Masrour and Sina Khamaki and Kimia Jazi and Erfan Ghoodjani and Teixeira, {Antonio L.}",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s). Brain and Behavior published by Wiley Periodicals LLC.",

year = "2025",

month = jan,

doi = "10.1002/brb3.70266",

language = "English (US)",

volume = "15",

journal = "Brain and Behavior",

issn = "2157-9032",

publisher = "John Wiley & Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Brain-Derived Neurotrophic Factor (BDNF) as a Potential Biomarker in Brain Glioma

T2 - A Systematic Review and Meta-Analysis

AU - Hasani, Fatemeh

AU - Masrour, Mahdi

AU - Khamaki, Sina

AU - Jazi, Kimia

AU - Ghoodjani, Erfan

AU - Teixeira, Antonio L.

PY - 2025/1

Y1 - 2025/1

N2 - Background: This systematic review and meta-analysis evaluates peripheral and CNS BDNF levels in glioma patients. Methods: Following PRISMA guidelines, we systematically searched databases for studies measuring BDNF in glioma patients and controls. After screening and data extraction, we conducted quality assessment, meta-analysis, and meta-regression. Results: Eight studies were included. Meta-analysis showed significantly reduced plasma BDNF levels in glioma patients versus controls (SMD: −1.0026; 95% CI: [−1.5284, −0.4769], p = 0.0002). High-grade gliomas had lower plasma BDNF (p = 0.0288). Tissue BDNF levels were higher in glioma patients (SMD: 1.9513; 95% CI: [0.7365, 3.1661], p = 0.0016) and correlated with tumor grade (p = 0.0122). Plasma BDNF levels negatively correlated with patient age (p = 0.0244) and positively with female percentage (p = 0.0007). Conclusion: BDNF is a promising biomarker in glioma, showing significant changes in plasma and tissue levels correlating with tumor grade, patient age, and gender.

AB - Background: This systematic review and meta-analysis evaluates peripheral and CNS BDNF levels in glioma patients. Methods: Following PRISMA guidelines, we systematically searched databases for studies measuring BDNF in glioma patients and controls. After screening and data extraction, we conducted quality assessment, meta-analysis, and meta-regression. Results: Eight studies were included. Meta-analysis showed significantly reduced plasma BDNF levels in glioma patients versus controls (SMD: −1.0026; 95% CI: [−1.5284, −0.4769], p = 0.0002). High-grade gliomas had lower plasma BDNF (p = 0.0288). Tissue BDNF levels were higher in glioma patients (SMD: 1.9513; 95% CI: [0.7365, 3.1661], p = 0.0016) and correlated with tumor grade (p = 0.0122). Plasma BDNF levels negatively correlated with patient age (p = 0.0244) and positively with female percentage (p = 0.0007). Conclusion: BDNF is a promising biomarker in glioma, showing significant changes in plasma and tissue levels correlating with tumor grade, patient age, and gender.

KW - BDNF

KW - biomarker

KW - brain neoplasms

KW - brain-derived neurotrophic factor

KW - glioblastoma

KW - glioma

UR - http://www.scopus.com/inward/record.url?scp=85214389201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85214389201&partnerID=8YFLogxK

U2 - 10.1002/brb3.70266

DO - 10.1002/brb3.70266

M3 - Review article

C2 - 39789839

AN - SCOPUS:85214389201

SN - 2157-9032

VL - 15

JO - Brain and Behavior

JF - Brain and Behavior

IS - 1

M1 - e70266

ER -

Brain-Derived Neurotrophic Factor (BDNF) as a Potential Biomarker in Brain Glioma: A Systematic Review and Meta-Analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this